- $13.18bn
- $19.87bn
- $3.12bn
- 78
- 52
- 99
- 90
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 944 | 580 | 1,030 | 2,131 | 3,121 |
Cost of Revenue | |||||
Gross Profit | 735 | 432 | 856 | 1,804 | 2,506 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 864 | 1,218 | 722 | 1,122 | 2,025 |
Operating Profit | 80.3 | -637 | 308 | 1,009 | 1,096 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 22.2 | -770 | 139 | 870 | 1,036 |
Provision for Income Taxes | |||||
Net Income After Taxes | 16.4 | -685 | 138 | 750 | 880 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 15.8 | -683 | 138 | 515 | 476 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 16.1 | -683 | 138 | 521 | 482 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.187 | -1.18 | 0.492 | 1.83 | 1.53 |
Dividends per Share |